Enhanced anti-inflammatory benefits of meloxicam-loaded lipid-core nanocapsules in a mouse pleurisy model: A comparative study with a free form drug

Abstract

Available online xxxKeywords: Inflammation Pleurisy Nanoparticles Cytokines Meloxicam a b s t r a c t The development of new treatments for inflammation continues to be of high interest, since long-acting effect is critical for patients. We investigated whether meloxicam-loaded lipid-core nanocapsules (M-NC) have an anti-inflammatory action superior to a free drug (M-F) on a mouse pleurisy model, by analyzing the time-course of leukocytes migration in the pleural fluid. Male adult Swiss mice were divided into six groups for each time (24; 48and 72 h) and were pretreated with blank nanocapsules (17 ml/kg) or M-NC (5 mg/kg) or free meloxicam (M-F) (5 mg/kg). After pretreatments, mice received saline (0.9%) or carrageenan (Cg) (1%) into pleural cavity. Four hours after Cg or saline administration, animals were killed, pleural cavity was washed and pleural fluid was collected for the determination of total leukocytes. Cytokines levels, differential leukocyte count and a-1-acid glycoprotein (AGP) levels were determined only at 48 h of pretreatment, which had effect on total leukocyte count. M-NC were effective against the increase in total and differential leukocyte counts and pleural exudate caused by Cg, while M-F had no effect. M-NC had superior

Amyloid-β peptide absence in short term effects on kinase activity of energy metabolism in mice hippocampus and cerebral cortex

“…Previously, it was reported that nanocapsules showed effective delivery of drugs to the brain and to inflamed tissues (Frozza et al 2010), (Bernardi et al 2012), (Ianiski et al 2012(Ianiski et al , 2016, (Villalba et al 2014). In this way, some characteristics of nanoparticulated systems, such as the carrier size, the polymer type, as well as their surface features, might induce steric stabilization of nanoparticles, inhibiting protein binding and increasing the blood circulation time (Brioschi et al 2007), (Bernardi et al 2009), (Kreuter 2014), (Voigt et al 2014).…”

“…The treatments were performed each other day, until the end of the experimental protocol (Ianiski et al 2012). The volume used for B-NC (17 ml/kg body weight) and equivalent dose of M-NC or M-F (5 mg/kg body weight) was chosen based on a previous study (Ianiski et al 2012(Ianiski et al , 2016, FRANCINE R. IANISKI et al (Villalba et al 2014). Mice belonging to aβ and Sham groups received the suspension containing B-NC.…”